Investigation for oncogenes relating to chemotherapy resistance of human malignant gliomas
| Project/Area Number |
14571295
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
SAWAMURA Yutaka Hokkaido University Hospital, Assist.Prof., 医学部・歯学部附属病院, 講師 (10235476)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITOH Tomoo Hokkaido University Hospital, Prof., 医学部・歯学部附属病院, 講師 (20301880)
IKEDA Jun Hokkaido University Hospital, Assist.Prof., 医学部・歯学部附属病院, 助手 (70332468)
NAGASHIMA Kazuo Hokkaido Univ., Grad.School of Med., Prof., 大学院・医学研究科, 教授 (50010377)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2002: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | Anti-OLIG2 antibody / Auxiliary diagnostic tooL / Human gliomas / Immunohistochemistry / Olig1 / Olig2 / Quantitative RT-PCR / oligodendroglioma / tumor marker / loss of heterozygosity / fluorescence in situ hybridization / microsatellite analysis / chemosensitivity |
|---|
| Research Abstract |
Because a specific group of oligodendrogliomas is susceptible to adjuvant therapy, it is important to elucidate the biological characteristics of these tumors. In situ hybridization analyses have revealed that Olig genes are expressed in oligodendroglial lineage cells and are highly expressed in oligodendrogliomas. To clarify whether OLIG is a tumor-specific marker for oligodendrogliomas, we have investigated the expression of Olig transcripts by semiquantitative RT-PCR assay and OLIG2 protein with a new antibody in a variety of glial tumors. The semiquantitative RT-PCR revealed that high levels of expression of Olig1 and Olig2 mRNAs were present in anaplastic oligodendrogliomas and anaplastic astrocytomas, while expression of these mRNAs in grade IV glioblastomas was lower than in grade II and grade III gliomas (p<0.01). Immunohistochemical analyses demonstrated that the mean immunopositive proportion of OLIG2 was 82% in anaplastic oligodendrogliomas, but only 34% in anaplastic astrocytomas. Therefore, although OLIG2 expression was detected in a range of gliomas not specific for oligodendrogliomas, the expression level in anaplastic oligodendrogliomas was more uniform and intense than that in other glial tumors. In conclusion, combining Olig mRNA expression and immunohistochemistry of OLIG2 enables oligodendrogliomas to be distinguished from glioblastomas and other astrocytic glial tumors.
|
Report
(3 results)
Research Products
(6 results)
